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Background: Mycobacterium tuberculosis (Mtb) infections are still a major cause of death among all infectious
diseases. Although 99% of individuals infected with Mtb develop a CD4+ Th1 and CD8+ T cell mediated immunity
as measured by tuberculin skin test, this results only in partial protection and Mtb vaccines are not effective.
Deviation of immune responses by pathogens towards a Th2 profile is a common mechanism of immune evasion,
typically leading to the persistence of the microbes.
Results: Here we tested the stimulatory capacity of selective Mtb antigens on human monocyte-derived dendritic
cell (DC) maturation and cytokine production. DC maturation markers CD80, CD86 and CD83 were readily
upregulated by H37Ra- and H37Rv-associated antigens, the 30-kDa (from Ag85 B complex) and 38-KDa Mtb antigens
only partially induced these markers. All Mtb antigens induced variable levels of IL-6 and low levels of IL-10, there was
no release of IL-12p70 detectable. Substantial IL-12p40 production was restricted to LPS or H37Ra and H37Rv
preparations. Although the proliferation levels of primary T cell responses were comparable using all the differentially
stimulated DC, the 30-kDa and 38-kDa antigens showed a bias towards IL-4 secretion of polarized CD4+ T cells after
secondary stimulation as compared to H37Ra and H37Rv preparations.
Conclusion: Together our data indicate that 30-kDa and 38-kDa Mtb antigens induced only partial DC maturation
shifting immune responses towards a Th2 profile.
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From the people infected worldwide with Mtb only about
5-10% develope disease, while the majority can control the
disease through NK cell and Th1 immune responses char-
acterized by the release of IFN-γ and TNF leading to the
cytotoxic activity of CD8+ T cells and macrophages. Sus-
ceptibility to Mtb is considered to result from a subopti-
mal immune response and therefore a vaccine against
Mtb would improve this status. However, no vaccine
based on Mtb is currently available. BCG as an attenuated
strain of M. bovis has been used as a vaccine against Mtb* Correspondence: m.lutz@vim.uni-wuerzburg.de
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reproduction in any medium, provided the orbut without achieving a reliable protection [1]. Thus, alter-
native vaccination strategies are urgently needed [2].
Currently modified BCG vaccines are the most com-
mon tested in clinical trials but also few selective Mtb
antigens have been tested for their capacity to stimulate
immune responses in order to use them as a vaccine [3].
A successful vaccine should induce strong CD8 and Th1
memory responses and at the same time avoid the in-
duction of immune tolerance mechanisms. Immune de-
viation towards Th2 responses is a hallmark of many
infections leading to microbial persistence [4]. Thus,
we wanted to investigate whether immune deviation
could be detected by selective Mtb components. We
studied these factors not as antigens presented on MHC
molecules but as factors to induce DC maturation. Thetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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DC-mediated immune responses of CD4+ T cells.
Initially, all types of DC maturation were believed to in-
duce DC immunogenicity. By establishing a semi-mature
stage of DC maturation we could demonstrate that ma-
tured DC nevertheless could act tolerogenic. TNF treat-
ment of murine bone marrow-derived DC led to their
partial maturation and after i.v. injection induced protect-
ive IL-10 producing T cells (Tr1) in the model of experi-
mental autoimmune encephalomyelitis (EAE) [5]. This
effect was antigen-specific and not dependent on by-
stander proteins [6]. Cytokine analysis revealed that also
IL-4 and IL-13 produced from CD4+ T and NKT cells
contributed to the protection, indicating a Th2 cell in-
volvement [7]. Interestingly, although injections of TNF/
DC induced a mixed Tr1/Th2 response when injected
alone, antigen-specific pre-treatment of mice with TNF/
DC did not boost subsequent Th2 cell responses such as
Leishamania major infection of BALB/c mice [8] or aller-
gic asthma [9]. This effect of tolerogenic mature DC is not
restricted to the murine system. Others showed that TNF/
PGE2-maturation of human monocyte-derived DC was re-
quired to perform cross-tolerance [10]. Thus, DC matur-
ation must not necessarily indicate the induction of
protective immunity.
Membrane and secreted molecules but also whole pro-
tein extracts of Mtb represent promising candidates in
Mtb vaccine development. The Ra and Rv strains have
been studied extensively and recent gene array analysis
indicates that the Rv strain is by far better in promoting
Th1 responses [11]. In this study, culture filtrate pro-
teins (CFPs) isolated from Mtb H37Rv and H37Ra
strains [12] were compared to find out whether at-
tenuation versus virulence would induce differences in
CD4+ T cell polarization. The 38-kDa protein repre-
sents an immunodominant phosphate-binding protein
that was originally identified in pulmonary tubercu-
losis and a model antigen to screen for Mtb infections
[13]. In mycobacterial culture fluid the antigen 85
complex B (Ag85B) is a major secretory component of
Mtb that is also considered as a candidate for a vac-
cine due to its protection in animal experiments. The
already commercially available 30-kDa protein is part
of the Ag85B complex and when expressed in BCG
shows more potent protection against Mtb [13]. Thus
CFP preparations as well as these two immunodominant
secretory proteins 30-kDa and 38-kDa antigens derived
from the virulent strain Mtb H37Rv [14,15] may represent
candidates for vaccine development. Since effective anti-
mycobacterial immune responses are of the Th1 and not
Th2 type, we developed a human CD4+ T cell polarization
system to test these antigens for their potential to shift
immune responses towards Th2 as a sign of immune
evasion.Here we addressed the questions whether the 30-kDa,
38-kDa or CFP preparations from H37Rv and H37Ra
were able to mount DC maturation in vitro and to instruct
the DC for a subsequent polarization of CD4+ T-helper
(Th) cell responses. To enable the polarization of a
substantial frequency of CD4+ T cells, we used the
superantigen SEB. The results indicate a partial activa-
tion/maturation of DC as detected by surface markers
and cytokine production. The 30-kDa and 38-kDa Mtb
antigens appeared weaker DC stimulators than the Ra
and Rv preparations. Primary T cell stimulations by
these DC revealed similar proliferation rates. However,
the secondary stimulation leading to polarized CD4+ T
cell responses showed some differences. While robust
IFN-γ production could be observed by all Mtb prepa-
rations, it was of note that the 30 kDa and 38 kDa anti-
gens also maintained IL-4 production as a sign of immune
deviation.
Results and discussion
The 30-kDa and 38-kDa Mtb antigens induce only a mild
upregulation of DC maturation markers and cytokine
production
Various mycobacterial components induce maturation of
DCs but mostly Mtb surface products have been investi-
gated [16]. The immunogenicity of the different Mtb
preparations was tested by their incubation with human
monocyte-derived DC in vitro. After 24 h of stimulation
positive control DC that were stimulated with LPS,
strongly upregulated the key surface markers CD80,
CD83 and CD86 (Figure 1). The Mtb preparations H37Rv
and H37Ra showed a low stimulatory capacity and the
30-kDa and 38-kDa preparations had only a weak or
even no effect on these markers (Figure 1). In compari-
son to the strong maturation by Mtb surface products
that was similar to LPS [16], only a mild upregulation
of typical maturation markers was observed here.
To further test the DC maturation capacity of Mtb an-
tigens, supernatants of the stimulated cells were analysed
for their cytokine content. Surprisingly, only the LPS con-
trol revealed measurable amounts of IL-12p70 but not the
mycobacterial antigens (not shown). While IL-6 release by
DCs was variable and highly donor-dependent, IL-10 pro-
duction could be observed at low amounts by LPS, H37Rv
and H37Ra (Figure 2). Consistently IL-12p40 was induced
by LPS, H37Rv and H37Ra but only at low concentrations
of below 1 ng/ml by the 30-kDa and 38-kDa antigens
(Figure 2).
These data indicate that especially the 30-kDa and 38-
kDa preparations induce only a partial DC maturation
that may lead to a tolerogenic or immune deviatory CD4+
Th2 cell response as observed in murine models [5,8]. In
fact, more recent gene profiling experiments indicate that
murine DCs matured only partially e.g. with TNF or
Figure 1 DCs show only a partial maturation on 30-kDa and 38-kDa Mtb antigen stimulation. DCs were generated from peripheral blood
monocytes of healthy donors and at day 5 of culture stimulated with 10 μg of the indicated Mtb antigens or LPS or left untreated in buffer as a
control for 24 h. Then cells were stained at the cell surface for the indicated markers (dotted or straight lines). Gray histograms show the markers
on immature DC (control). The experiment is representative of 5 independent experiments.
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of only 24 regulated inflammatory genes identified for
Th2-inducing DCs, whereas the same gene set as well as
additional other genes induced by bacterial LPS result in
full DC maturation and Th1 induction [9]. Interstingly,Figure 2 Mtb antigens lead to moderate cytokine production of DCs.
donors and at day 5 of culture stimulated with 10 μg of the indicated Mtb
indicated cytokines were detected from the cell supernatants. The two exp
high inter-individual variations. They are representative of 5 independent e
the ELISA.after restimulation of peripheral blood cells from patients
with recurrent tuberculosis with the 30-kDa antigen we
found depressed levels of IL-12 previously [17]. In the fol-
lowing experiments we addressed the question whether
such quantitative differences in DC maturation may affectDCs were generated from peripheral blood monocytes of healthy
antigens or LPS or left untreated in buffer as a control for 24 h. The
eriments shown were performed from two different donors and show
xperiments. Error bars represent the SEM of duplicate samples from
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responses. From our murine data we hypothesized that
also partial human DC maturation as observed for the 30-
kDa and 38-kDa preparations may lead to minor differ-
ences in the T cell proliferation but significantly alter Th1/
Th2 cytokine profiles.
Similar allogeneic and SEB-dependent T cell priming
capacity by the differentially Mtb-matured DC
We then analysed whether the differential DC matur-
ation conditions would result in diverging T cell priming
capacities. When the differentially matured DCs were used
to prime allogeneic T cells in vitro all stimuli appeared re-
markably similar to the LPS control (Figure 3a). SimilarFigure 3 Mtb-matured DCs show similar allogeneic and SEB-specific T
the indicated reagents and then used to stimulate allogeneic T cells (a) or
was assessed by [3H]-thymidine incorporation. a. The two experiments sho
represent the SEM of triplicate samples from one proliferation assay. b. The
represent the SEM of triplicate samples from one proliferation assay. For th
each experiment are shown. Error bars represent the SEM of triplicate samp
different donors.proliferation rates were also obtained by stimulating syn-
geneic T cells with the differentially matured DCs and the
superantigen SEB (Figure 3b). Thus, despite strong differ-
ences on DC maturation markers and cytokine profiles,
the capacities to stimulate primary T cells did not differ
substantially between the matured DC. The discrepancies
between diverging surface marker expressions by DCs but
similar T cell proliferation rates may indicate that not the
quantity of the T cell response but the quality may have
changed. Former observations in the murine system
showed that DCs that were stimulated with Trypanosoma
antigens induced very similar proliferation rates of T cells
after injection in vivo [9]. However, the qualities of T
helper cell polarization differed markedly. Therefore we setcell priming capacities. DC were stimulated at day 5 for 24 h with
autologous T cells in the presence of SEB (b). After 3 days proliferation
wn are representative of 3 independent experiments. Error bars
data of 4 experiments are shown. For experiment 1 the error bars
e experiments 2–4 data for the highest/optimal proliferation values of
les of one proliferation assay. Note high variations between the
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T cells could be tested.
The 30-kDa and 38-kDa Mtb antigens maintain Th2 cell
responses
Previously we found that a quantitatively weaker T cell
stimulation by DC may result in the same T cell prolifera-
tion rates but different polarizations into CD4+ T helper
(Th) cell subsets [18]. Since the frequency of naive
antigen-specific T cells from PBMCs is too low to be
followed by any MHC II-restricted peptide stimulation
in vitro, we used a superantigen system where higher
naive antigen-specific frequencies of T cells can be ac-
tivated during T cell priming [19]. In this system we
explored the Th1 or Th2 subset polarization of the
Mtb antigen-matured DC. Primary SEB-stimulated T cells
were restimulated after 7 days with PMA/Ionomycin and
their supernatants tested for cytokine release. All groups
of stimulated T cells released substantial amounts of
IFN-γ and IL-10 with no significant differences (Figure 4).
However, T cells that were stimulated by 30-kDa- or
38-kDa-matured DC maintained a high IL-4 release as
compared to immature (SEB-treated) DC, although the
30-kDa protein showed only as a trend (Figure 4).
When the IFN-γ/IL-4 ratio was calculated the 38-kDa
antigen showed the strongest IL-4 bias although no
significance was achieved by this calculation (Figure 4).
These data indicate that DCs matured with the 38-kDa
antigen and as a trend also with the 30-kDa antigen,Figure 4 DCs stimulated with the 30-kDa and 38-kDa Mtb antigens le
antigens or LPS or left untreated and simultaneously loaded with the supe
T cells for 7 days. Then T cells were restimulated for 3 days by PMA/Ionom
Error bars represent the pooled mean data from 4 independent experimen
pooled ratios are shown. Statistical significance was tested using one-way Aallow SEB-specific T cell responses biased towards a
Th2 profile, similar to immature (SEB-treated) DCs.
Although immune responses tested at the level of DCs
against intracellular Mtb and many of their antigens are
dominated by IFN-γ producing CD8+ killer T cell and
Th1 responses [20], also Th2 responses have been ob-
served after infection of human monocytes with BCG
prior to differentiation into DCs [21]. Treatment of
PBMCs with peptides derived from the regions of differ-
ence (RD) antigens 12, 13 and 15 expressed by Mtb but
not BCG led to Th2 cytokine production [22]. Moreover,
the presence of regulatory T cells and Th2 cells may be
lined to infection susceptibility to Mtb [23]. In fact, pa-
tients suffering from diabetes mellitus are more suscep-
tible to tuberculosis development and this could be
linked to a Th2-bias of their anti-Mtb responses [24].
We provide evidence for two novel Mtb antigens (30 kDa
and 38-kDa) that induce Th2 responses in vitro in spite of
their capacity to elicit only incomplete DC maturation.
Conclusions
Here we showed that the 30-kDa and 38-kDa antigens
as Mtb components induce only a partial DC maturation
leading to a Th2 shift in T cell polarization assays. Since
efficient immune protection from intracellular bacteria
such as Mtb depends on IFN-γ dependent CD4+ Th1
and cytotoxic CD8+ T cell responses, the observed Th2
shift can be envisaged as an immune escape mechanism
by Mtb. Thus, using the two 30-kDa and 38-kDa antigensad to a Th2 shift in vitro. DCs were stimulated with the different Mtb
rantigen SEB. After washing the DCs were co-cultured with autologous
ycin to induce cytokine release. Cytokines were measured by ELISA.
ts. The IFN-γ/IL-4 ratio was calculated from 4 experiments and the
NOVA test with Bonferroni’s post test. * = p < 0.05.
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Therefore these findings may have implications for vaccin-
ation strategies against Mtb [3] or for the pathological out-
comes observed in Mtb infected individuals suffering also
from other diseases such as diabetes [24]. Although Mtb
interferes with several innate immune receptors to raise
an immune response [25] it has developed several mecha-
nisms of immune evasion strategies to prevent elimination
[26]. Although infected individuals generate immune re-
sponses and most people can control the infection they
never reach complete Mtb elimination and microbial ster-
ility [27]. Thus, in most cases Mtb infections represent a
fine balance between immune reaction and immune eva-
sion. The latter mechanisms may also be envisaged to pre-
vent immune pathology by too strong immune reactions.
Together this reflects the co-evolution strategy of Mtb
[28]. To develop effective vaccines without strong side ef-
fects this fine balance and all participating mechanisms
have to be considered. A large part of the immune evasion
by Mtb is based on the persistent or latent infection of
macrophages and the TLR-2-dependent down-regulation
of antigen presenting function by Mtb in these macro-
phages [29]. The emerging role of DCs as regulators of tu-
berculosis disease has been elucidated only during the last
years by genome-wide transcriptome analyses [28]. It is
well possible that also the induction of suboptimal matur-
ation of DCs reflects another mechanism of Mtb to target
antigen presenting cells. In our system we studied select-
ive Mtb antigens and found that the two antigens 30-kDa
and 38-kDa of Mtb may be involved in immune evasion at
the level of DCs. The quality of DC manipulation by Mtb
appears to differ from what is known from macrophages.
While for macrophages the MHC-dependent antigen pre-
senting function seems to dominate our data point to an
intact antigen presentation as observed in the allo-MLR
and SEB-priming, but a bias towards Th2 immunity.
These in vitro data require now further validation in vivo
but may indicate that the 30-kDa and 38-kDa antigens
represent suboptimal Mtb vaccine candidates.
Methods
Dendritic cell generation from PBMC
Peripheral blood was depleted of thrombocytes and plasma
by Trima Accel® apheresis system (CaridianBCT, #80300)
and obtained from the Blood Bank of the University of
Würzburg from healthy blood donors with consent of the
Ethical Committee of the University of Wuerzburg. PBMC
were isolated by centrifugation in Lymphocyte Separation
Medium LSM 1077 (PAA Laboratories GmbH, Cölbe) and
plated in sterile Tissue culture dishes 100 mm (Greiner No
664160) at a density of 5×107 cells per dish in 10 ml
culture medium: RPMI 1640 without L-Glutamine
(PAA Laboratories GmbH, Cölbe) with 1% heat-inactivated
human AB-Serum (PAA Laboratories GmbH, Cölbe),2 mM L-Glutamin (PAA 200 mM) and Penicillin/
Streptomycin (PAA 100x) and incubated at 37°C, 5%
CO2 for 1 h. After 1 h the non-adherent-fraction (NAF) was
removed and deep-frozen at −80°C for later use as T cell
source for the allogeneic mixed lymphocyte reaction (MLR).
Then the dishes were washed twice by gentle rinsing with
PBS without Ca2+ or Mg2+. Afterwards 10 ml of fresh, warm
culture medium was added on the dish with the adherent
monocytes and incubated for overnight at 37°C, 5% CO2. At
day one the culture medium was carefully removed
that loosely adherent cells remained unaffected and
new culture medium containing 800 U/ml GM-CSF
(Leukine® Sargramostim, Bayer) and 250 U/ml IL-4
(Strathmann Biotec AG Hamburg) was added. Cyto-
kines were added again at day 3 in 3 ml fresh medium
(containing GM-CSF 800 U/ml and IL-4 250 U/ml) per
dish and cultured until day 5.
Mtb and other substances for DC maturation
H37Ra and H37Rv: CFPs of Mtb H37Rv and H37Ra
were isolated by growing tubercle bacilli in Sauton’s syn-
thetic medium as a stationary pellicle culture. Briefly,
culture supernatants were centrifuged at 15,000 × g for
1 h, sterilized by filtration (0.22-μm pore size), and con-
centrated by ultrafiltration (Amicon Ultra-15 centrifugal
filter unit with a 10-kDa-molecular- mass cutoff; Millipore).
Polymyxin B columns were used to remove endotoxin in
mycobacterial antigens after purification followed by sterile
filtration. The 30-kDa antigen (Ag85 B complex) and
38-kDa antigens were purified from 6-week culture fil-
trates of Mtb H37Rv.
At day 5 the immature DC were harvested and distrib-
uted into 24-well-plates (Greiner) at a density of 5×105
cells per well in 1 ml culture medium without cytokines.
These DCs were stimulated with different mycobacterial
antigens at 10 μg/ml, LPS (E. coli 0127:B8, Sigma) at
0.1 μg/ml or left unstimulated as a negative control. To
determine the cytokine production of DCs, the superna-
tants of stimulated cells were collected and tested by
ELISA kits for IL-6 (R&D Systems), IL-10 (R&D Systems),
IL-12p40 and IL-12p70 (BD Biosciences).
FACS analysis
DC were matured or left untreated at day 5 and phenotyped
at day 7 with a panel of antibodies detecting the following
surface markers: CD80 PE (mIgG1), CD83 APC (mIgG1),
CD86 FITC (mIgG1) and HLA DR FITC (mIgG2a) (all BD
Biosciences). For the staining 5×104 cells were incubated
with the antibodies and the respective isotype control was
diluted 1:100 with buffer (PBS 0,1% BSA, 0,2% sodium
azide, 0,5 M EDTA) at 4°C for 30 min. Then the cells
were washed and analysed with an LSR II flow cytometer
(BD) and alalyzed with FlowJo Cytometry Analysis Soft-
ware (Tree Star Inc. Olten).
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At day 5 of DC culture NAF from allogeneic blood do-
nors were prepared for allogeneic MLR and cultured
over night. At day 6 the DCs matured with the stimuli
indicated in the figure legend (see also above) were
harvested and seeded into two 96-well-flatbottom-plates
as triplicates at titrated amounts of DCs as indicated.
Then 2× 105 NAF from a different donor were added.
After 3 days cultures were pulsed with 1 μCi/well [3H]-
Thymidine (Hartmann Analytic, Braunschweig) for 16 h
and then harvested onto glass fiber filter mats (PerkinElmer,
USA), scintillation wax added and counted in a 1450
Microbeta Counter (Tomtec) to measure cell proliferation.
Stimulation of secondary SEB-specific responses
At day 5 of DC culture the frozen autologous NAF were
thawed and cultured over night. DCs were plated in two
96-well-flatbottom-plates as triplicates at titrated amounts.
Responder cells were added at 2×105 NAF from the same
donor with 10 or 100 ng/ml Staphylococcus aureus entero-
toxin B (SEB) (Sigma Aldrich). In parallel, for the sec-
ondary SEB stimulation, 4×104 DCs were plated in
24-well-plates together with 1×106 NAF cells per well in
culture medium containing 10 ng/ml SEB. SEB showed
a very mild maturation effect on DCs (not shown). Six
days later T cell cultures were harvested, distributed into
96-well-plates at a density of 2×105 cells per well and
restimulated with 10 ng/ml PMA (Sigma Aldrich) and
500 ng/ml Ionomycin (Sigma Aldrich, Streptomyces
conglobatus). After 3 days supernatants were collected for
analysis of cytokine production of IL-10 (R&D Systems),
IL-4 and IFN-γ (BD Biosciences) by ELISA kits.
Statistics
Statistical significance was tested with the Prism® soft-
ware (version 4.0a, GraphPad Inc.) using one-way ANOVA
test with Bonferroni’s Multiple Comparison post test.
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enterotoxin B.
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